Minimal clinically important change on the unified Parkinson's disease rating scale
Identifieur interne : 001845 ( Main/Corpus ); précédent : 001844; suivant : 001846Minimal clinically important change on the unified Parkinson's disease rating scale
Auteurs : Anette Schrag ; Cristina Sampaio ; Nicholas Counsell ; Werner PoeweSource :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
English descriptors
- KwdEn :
Abstract
The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20914
Links to Exploration step
ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name><affiliation><mods:affiliation>GlaxoSmithKline, Harlow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Clinic, Innsbruck, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48D</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20914</idno><idno type="url">https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001845</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name><affiliation><mods:affiliation>GlaxoSmithKline, Harlow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Clinic, Innsbruck, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08">2006-08</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1200">1200</biblScope><biblScope unit="page" to="1207">1207</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9A21C7C1629235028808E950CFCF237D12AFB48D</idno><idno type="DOI">10.1002/mds.20914</idno><idno type="ArticleID">MDS20914</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>UPDRS</term><term>Unified Parkinson's Disease Rating Scale</term><term>minimal clinically important change</term><term>minimal clinically meaningful improvement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anette Schrag MD, PhD</name><affiliations><json:string>Royal Free and University College Medical School, University College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Nicholas Counsell BSc</name><affiliations><json:string>GlaxoSmithKline, Harlow, United Kingdom</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University Clinic, Innsbruck, Austria</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>minimal clinically important change</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>minimal clinically meaningful improvement</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Unified Parkinson's Disease Rating Scale</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>UPDRS</value></json:item></subject><articleId><json:string>MDS20914</json:string></articleId><language><json:string>eng</json:string></language><abstract>The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>7.295</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1435</abstractCharCount><pdfWordCount>4487</pdfWordCount><pdfCharCount>29657</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>234</abstractWordCount></qualityIndicators><title>Minimal clinically important change on the unified Parkinson's disease rating scale</title><genre><json:string>article</json:string></genre><host><volume>21</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>1207</last><first>1200</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.20914</json:string></doi><id>9A21C7C1629235028808E950CFCF237D12AFB48D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Royal Free and University College Medical School, University College London, London NW3 2PF, United Kingdom</p></note><affiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author><persName><forename type="first">Nicholas</forename><surname>Counsell</surname></persName><roleName type="degree">BSc</roleName><affiliation>GlaxoSmithKline, Harlow, United Kingdom</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Clinic, Innsbruck, Austria</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1200">1200</biblScope><biblScope unit="page" to="1207">1207</biblScope></imprint></monogr><idno type="istex">9A21C7C1629235028808E950CFCF237D12AFB48D</idno><idno type="DOI">10.1002/mds.20914</idno><idno type="ArticleID">MDS20914</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>minimal clinically important change</term></item><item><term>minimal clinically meaningful improvement</term></item><item><term>Parkinson's disease</term></item><item><term>Unified Parkinson's Disease Rating Scale</term></item><item><term>UPDRS</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-08-14">Received</change><change when="2006-01-06">Registration</change><change when="2006-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v21:8</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2006-08">August 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="240" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20914</doi><idGroup><id type="unit" value="MDS20914"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-08-14"></event><event type="manuscriptRevised" date="2005-12-28"></event><event type="manuscriptAccepted" date="2006-01-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-05-03"></event><event type="firstOnline" date="2006-05-03"></event><event type="publishedOnlineFinalForm" date="2006-08-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1200</numbering><numbering type="pageLast">1207</numbering></numberingGroup><correspondenceTo>Royal Free and University College Medical School, University College London, London NW3 2PF, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20914.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="7"></count><count type="referenceTotal" number="37"></count><count type="wordTotal" number="5788"></count></countGroup><titleGroup><title type="main" xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title><title type="short" xml:lang="en">Clinically Significant Change of UPDRS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>a.schrag@medsch.ucl.ac.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Nicholas</givenNames><familyName>Counsell</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>GlaxoSmithKline, Harlow, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University Clinic, Innsbruck, Austria</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">minimal clinically important change</keyword><keyword xml:id="kwd2">minimal clinically meaningful improvement</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">Unified Parkinson's Disease Rating Scale</keyword><keyword xml:id="kwd5">UPDRS</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Minimal clinically important change on the unified Parkinson's disease rating scale</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Clinically Significant Change of UPDRS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Minimal clinically important change on the unified Parkinson's disease rating scale</title></titleInfo><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</affiliation><description>Correspondence: Royal Free and University College Medical School, University College London, London NW3 2PF, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicholas</namePart><namePart type="family">Counsell</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>GlaxoSmithKline, Harlow, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Clinic, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-08</dateIssued><dateCaptured encoding="w3cdtf">2005-08-14</dateCaptured><dateValid encoding="w3cdtf">2006-01-06</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">7</extent><extent unit="references">37</extent><extent unit="words">5788</extent></physicalDescription><abstract lang="en">The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>minimal clinically important change</topic><topic>minimal clinically meaningful improvement</topic><topic>Parkinson's disease</topic><topic>Unified Parkinson's Disease Rating Scale</topic><topic>UPDRS</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1200</start><end>1207</end><total>8</total></extent></part></relatedItem><identifier type="istex">9A21C7C1629235028808E950CFCF237D12AFB48D</identifier><identifier type="DOI">10.1002/mds.20914</identifier><identifier type="ArticleID">MDS20914</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001845 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001845 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48D
|texte= Minimal clinically important change on the unified Parkinson's disease rating scale
}}
| This area was generated with Dilib version V0.6.23. |  |